[{"id":"44bc5480-d166-44d8-a132-2ee768e67fe6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07069699","created_at":"2025-07-19T14:11:58.704Z","updated_at":"2025-07-19T14:11:58.704Z","phase":"Phase 1/2","brief_title":"Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene","source_id_and_acronym":"NCT07069699","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pidnarulex (CX-5461)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/19/2025","start_date":" 09/19/2025","primary_txt":" Primary completion: 09/19/2027","primary_completion_date":" 09/19/2027","study_txt":" Completion: 09/19/2027","study_completion_date":" 09/19/2027","last_update_posted":"2025-07-17"},{"id":"ffde309b-8c51-4b41-b83c-bcf6504849f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06606990","created_at":"2025-02-25T20:15:32.283Z","updated_at":"2025-02-25T20:15:32.283Z","phase":"Phase 1","brief_title":"Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers","source_id_and_acronym":"NCT06606990","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pidnarulex (CX-5461)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/09/2025","start_date":" 09/09/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-16"},{"id":"e1343c11-13a7-4445-ac57-b18f14eecc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890613","created_at":"2021-05-18T12:02:00.454Z","updated_at":"2024-07-02T16:35:24.671Z","phase":"Phase 1","brief_title":"Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation","source_id_and_acronym":"NCT04890613","lead_sponsor":"Senhwa Biosciences, Inc.","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA1 mutation • PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pidnarulex (CX-5461)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/08/2021","start_date":" 09/08/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-01-03"},{"id":"75416a43-f5aa-461e-93c8-fe71b8166f6e","acronym":"REPAIR","url":"https://clinicaltrials.gov/study/NCT05425862","created_at":"2022-06-21T23:54:38.365Z","updated_at":"2024-07-02T16:35:26.578Z","phase":"Phase 1","brief_title":"Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT05425862 - REPAIR","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • pidnarulex (CX-5461)"],"overall_status":"Suspended","enrollment":" Enrollment 48","initiation":"Initiation: 10/21/2022","start_date":" 10/21/2022","primary_txt":" Primary completion: 07/12/2024","primary_completion_date":" 07/12/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-12-11"},{"id":"44769731-512c-4c72-a9b8-8e09755a0ba1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02719977","created_at":"2021-01-18T13:18:23.237Z","updated_at":"2024-07-02T16:35:40.891Z","phase":"Phase 1","brief_title":"A Phase I Study of CX5461","source_id_and_acronym":"NCT02719977","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pidnarulex (CX-5461)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 06/13/2016","start_date":" 06/13/2016","primary_txt":" Primary completion: 01/30/2020","primary_completion_date":" 01/30/2020","study_txt":" Completion: 01/18/2023","study_completion_date":" 01/18/2023","last_update_posted":"2023-08-04"}]